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LEADING ARTICLEThe Chronic Cerebrospinal Venous Insufﬁciency Debate
S. Onida a, A.H. Davies a,*Multiple Sclerosis (MS) is a chronic, inﬂammatory, demye-
linating disease of the central nervous system. The patho-
genesis of MS is as yet unknown, although the most widely
accepted hypothesis is a T-cell mediated autoimmune
response.1
Chronic cerebrospinal venous insufﬁciency (CCSVI) is a
fairly recent hypothesis diverging from the generally
accepted theories regarding MS aetiology. Developed by
Professor Paolo Zamboni of the University of Ferrara, it has
been deﬁned as “a syndrome characterised by multiple
stenoses of the internal jugular and/or azygous veins and
formation of collateral venous channels”.2 The hypothesis,
or “Big Idea” as described in his 2006 paper,3 suggests a link
between these anatomical abnormalities and MS by draw-
ing parallels with the pathophysiology of chronic venous
disease. According to the CCSVI theory, chronic cerebral
venous hypertension, secondary to ineffective drainage by
abnormal venous channels, may trigger an inﬂammatory
process leading to the development of MS.
Certainly, there are parallels between the two disease
processes. The demyelinating plaques characterising MS
form in a perivenular distribution,4 and histological studies
have revealed evidence of venous damage in the form of
ﬁbrin cuff formation, haemosiderin deposition, and
thrombosis.3 These ﬁndings are similar to the damage that
perivenous tissues display in the lower limbs of patients
with chronic venous insufﬁciency. However, excess iron
deposition and inﬂammatory lesions are not speciﬁc to MS
and are also found in other neurodegenerative disorders,
including Alzheimer’s and Parkinson’s disease,5 as well as in
the ageing brain.
Over the last 7 years, the CCSVI theory has been a cause
of turmoil in the MS community, involving patients, neu-
rologists, and vascular surgeons. This has led to the litera-
ture being inundated with highly heterogenous reports,
some supporting the theory and others challenging it. The
ﬁrst issue is the actual deﬁnition of CCSVI. According to the
“Zamboni criteria”, CCSVI is a diagnosis made on duplex
imaging, where two out of ﬁve standards based on the
detection of reﬂux or stenosis in the extracranial venous
system6 are required to diagnose the condition. One of
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None of the matched healthy controls were found to ﬁt the
criteria on either duplex or venography.6 A further study
revealed 100% sensitivity and speciﬁcity for the application
of the criteria in the diagnosis of MS.7
However, these ﬁndings have not been replicated by
other study groups,8,9 with the presence of CCSVI in MS
patients ranging from 0%10,11 to 76%.12,13 Those reports
identifying an increased prevalence of CCSVI in MS could
not support a causative relationship.12,13 This heterogeneity
was recognised by Zamboni himself, and was deemed to be
due to differing duplex techniques, training, and experience
in individual units.14 However, a more recently published
large, multicentre case-control study found no association
between CCSVI and MS.15 Furthermore the European So-
ciety of Neurosonology and Cerebral Haemodynamics is-
sued a statement criticising and raising concerns with
regards to the Zamboni criteria, describing them as incor-
rect and not validated.16 Recent studies suggest that
extracranial venous haemodynamics naturally ﬂuctuate,17,18
making Duplex ultrasound (US) assessment completely
unreliable.
The issue of reproducibility of venous duplex assessment
is crucial to the CCSVI debate. Rodger et al.10 addressed this
in their recent case-control study. This Canadian group
imaged neck and deep cerebral veins using US and magnetic
resonance imaging (MRI), with the primary objective being
the detection of the “Zamboni criteria” in 100 randomly
selected patients with different subtypes of MS compared
with age- and sex-matched healthy controls. Bearing in
mind the debate surrounding duplex US, the Canadian
group had also ensured that their ultrasonographers were
trained under Professor Zamboni and his colleagues via
direct supervision in Ferrara. Despite using the same im-
aging methodology, Rodger et al. were unable to replicate
the previously published results by the Zamboni group,
identifying only one MS patient out of their 200 participants
in whom the duplex criteria for CCSVI were met. In addition,
magnetic resonance (MR) venography assessment found no
signiﬁcant evidence of structural venous abnormalities in
the extracranial vessels between MS patients and controls.
Assessment of both intra and extracranial venous blood
ﬂow also failed to reveal any signiﬁcant difference between
the two groups. This paper, by using the same diagnostic
criteria as the Zamboni group and reproducing their US
ﬁndings via MR venography, provides compelling evidence
against the existence of CCSVI in MS.
In addition to the discrepancies in the reported rates of
CCSVI amongst MS patients, the Zamboni criteria have also
been observed in other neurological diseases12 and in
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control studies. Thapar et al.20 also found variability in the
sensitivities and speciﬁcities of CCSVI for MS, highlighting
the heterogeneity in published studies.
Given the conﬂicting evidence in the literature, especially
the recent Canadian study, is there evidence/justiﬁcation to
“treat” this condition by endovascular means (venoplasty
and/or stenting). Once again, opinion is heavily polarised.
Supporters of the CCSVI theory suggest that by treating the
anatomical abnormalities via the “liberation procedure”, the
signs and symptoms of MS can be improved. In the original
pilot study,21 Zamboni performed percutaneous transluminal
angioplasty of the internal jugular and/or azygous veins
reporting promising results, with no adverse events, a sig-
niﬁcant improvement in functional scores, and a reduction in
T2 lesions on MRI. Other studies have reported outcomes
supporting endovenous intervention, describing low
complication rates22 and improved functional outcomes.23
There are, however, plenty of worrying reports in the
literature regarding this mode of treatment. Published
complications of the “liberation procedure” include ar-
rhythmias, direct trauma to or dissection of the vein,
thrombosis,24 puncture site complications (including hae-
matoma formation), and fatal myocardial infarction.25 Fatal
intracranial haemorrhage and stent migration requiring
thoracotomy26 have also been described. Patients have
presented to geographically distant units with complica-
tions of their initial procedure.27 A largely unknown number
of patients, desperate for intervention, have resorted to a
form of medical tourism,28 with interventions being carried
out privately abroad. Reports include travel to the USA,
Bulgaria, Poland, and Mexico. Procedures in these countries
may be performed privately in an unregulated manner,
making it all the more challenging to treat patients pre-
senting with complications. Unfortunately, complication
data reporting is sparse and lacking long-term follow-up.
Following the positive results of the original pilot study,
endovenous treatment of CCSVI has gathered momentum
among patient groups. In the era of social media, information
on the condition and its treatment has spread like wildﬁre,
enabling patients to actively engage in the debate. Social
media portals (including blogs, facebook, and YouTube) have
been employed by patients to describe their post-treatment
experiences, which are largely positive.29,30 Public opinion
generally holds CCSVI in high regard, with those challenging
the theory being described as conspiring to deny treatment
to patients.30 It is clear to see why this might be. While
current treatment for MS is aimed at reducing the severity
and frequency of attacks, and to slow disease progression, a
cure still does not exist. The development of an intervention
that could free patients from a debilitating, chronic disease is
obviously extremely desirable.
Despite the media hype, the evidence for intervention in
CCSVI is confusing, at best, and needs to be interpreted
with caution. The Cardiovascular and Interventional Radio-
logical Society of Europe released a statement in 2011
warning against intervention in CCSVI owing to the lack of
high-quality, randomized trial data. They recommended thatpercutaneous angioplasty or stenting should not be offered
to MS patients unless within a clinical trial.31 In 2012, the
US Food and Drug Administration released a statement32
warning of the potential dangers of intervention in CCSVI
and advising against experimental procedures.
New theories such as CCSVI should, however, be
welcomed and openly investigated using high-quality
studies such as blinded randomised controlled studies.
However, this should be under the strict regulation of
ongoing clinical trials or as part of registry data collection,
so as to ensure that patients are adequately followed up
and long-term data analyses are possible. Randomised trials
are currently underway to investigate intervention in CCSVI
and the results are awaited. Until then, the debate con-
tinues. However, there is increasing evidence that the initial
excitement with respect to CCSVI has not been supported
by the more recent cohort studies and the early randomised
controlled trials.REFERENCES
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